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Abstract Nitric oxide (NO) induces apoptosis in thymocytes, 
peripheral T cells, myeloid cells and neurons. Here we show that 
NO is highly efficient in inducing mitochondrial permeability 
transition, thereby causing the liberation of apoptogenic factors 
from mitochondria which can induce nuclear apoptosis (DNA 
condensation and DNA fragmentation) in isolated nuclei in vitro. 
In intact thymocytes, N O triggers disruption of the mitochon-
drial transmembrane potential, followed by hypergeneration of 
reactive oxygen species, exposure of phosphatidyl serine on the 
outer plasma membrane leaflet, and nuclear apoptosis. Inhibitors 
of mitochondrial permeability transition such as bongkrekic acid 
and a cyclophilin D-binding cyclosporin A derivative, /V-methyl-
Val-4-cyclosporin A, prevent the mitochondrial as well as all 
post-mitochondrial signs of apoptosis induced by NO including 
nuclear DNA fragmentation and exposure of phosphatidylserine 
residues on the cell surface. These findings indicate that NO can 
cause apoptosis via triggering of permeability transition. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Nitric oxide (NO) is a pleiotropic mediator that, among 
other biological effects, causes apoptosis in a variety of cell 
types including macrophages, thymocytes, T cells and neurons 
[1-5]. It is now known that nuclear apoptosis is preceded by 
the disruption of the mitochondrial t ransmembrane potential 
(A *Fm) due to the opening of mitochondrial permeability tran-
sition (PT) pores [6-14]. This applies to different cell types 
(neurons, fibroblasts, B and T lymphocytes, pre-B cells and 
thymocytes, myelomonocytic cells) and to various apoptosis 
inducers (growth factor withdrawal, tumor necrosis factor, 
ceramide, glucocorticoids, positive and negative selection, gen-
otoxic stress, hyperexpression of Bax) (reviewed in ref. [15]). 
Physiological (sub-micromolar) concentrations of N O po-
tently and reversibly deenergize mitochondria and inhibit sev-
eral mitochondrial enzymes including aconitase and cyto-
chrome c oxidase [16,17]. In addition, peroxynitrate has 
been shown to induce mitochondrial PT [18,19]. Here we 
show that mitochondria treated with N O donors release apop-
togenic factors when undergoing permeability transition. In 
contrast, inhibition of PT by specific drugs including bong-
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krekic acid (BA), as well as by cyclosporin A (CsA) and a 
non-immunosuppressive CsA derivative, abolishes mitochon-
dria-mediated nuclear apoptosis, both in vitro and in cells. 
Our results are compatible with the hypothesis that N O in-
duces apoptosis via triggering mitochondrial PT. 
2. Materials and methods 
2.1. Cells and in vitro culture conditions 
Thymocytes from 30^15-day-old BALB/c mice were cultured at a 
final concentration of 1 X 106 cells/ml in RPMI 1640 supplemented 
with 10% FCS, L-glutamine, HEPES and antibiotics, and cultured 
in the presence of the indicated dose of S-nitroso-JV-acetylpenicill-
amine (SNAP), 1,3-morpholinosydnomine (SIN-1), S-nitroso-gluta-
thione (GSNO; all from Sigma, St. Louis, MO, USA), bongkrekic 
acid (BA; 50 uM; gift from Dr. Hans J. Duine, Delft University, The 
Netherlands), cyclosporin A (CsA; 10 uM), JV-methyl-Val-4-CsA 
(SDZ; 10 uM; kindly provided by Sandoz, Basel, Switzerland) 
and/or /V-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (Z-
VAD.fmk; 50 uM; enzyme systems) [20,21]. NO production was de-
termined using the diazotation reaction of Griess, with NaN02 as 
standard [22]. 
2.2. Mitochondrial swelling 
Mitochondria were purified from BALB/c mouse livers, on a Percoll 
gradient [23], and were stored on ice in B buffer (400 mM mannitol, 
10 mM PO4H2K, 5 mg/ml bovine serum albumin, and 50 mM Tris-
HC1, pH 7.2) for up to 4 h. For determination of large amplitude 
swelling, mitochondria were washed and resuspended in buffer B (100 
ug protein/10 JJ.1 buffer), followed by addition of 90 uM CFS buffer 
(300 nM mannitol, 100 mM sucrose, 2 mM NaCl, 2.5 mM P04H2K, 
0.5 mM EGTA, 2 mM Cl2Mg, 5 mM pyruvate, 0.1 mM PMSF, 2 mM 
ATP, 50 ug/ml creatinine phosphokinase, 10 mM phosphocreatine, 
1 mM dithiothreitol, and 10 mM HEPES-NaOH pH 7.4), and record-
ing absorption at 540 nm in a spectrophotometer (model DU 7400) as 
described [11]. The loss of absorption induced by ?er-butylhydroper-
oxide (50 uM) within 5 min was considered 100% large amplitude 
swelling. Supernatants of mitochondria (15 000Xg, 1 h, 4°C) were 
obtained after 5 min of incubation at 20°C and tested for apoptogenic 
activity on isolated nuclei, as described below. 
2.3. Cell free system of apoptosis 
Nuclei from mouse liver were purified on a sucrose gradient, as 
described [24], and were resuspended in CFS buffer (neg. control) or 
in mitochondrial supernatants. DNA fragmentation of nuclei was 
assessed using terminal desoxyribonucleotidyltransferase to incorpo-
rate fluorescein-12-dUTP into nuclei, following the manufacturer's 
protocol (TUNEL method, Boehringer-Mannhein). Briefly, nuclei 
were incubated 1 h at 37°C with 50 ul of staining buffer: 0.3 nmol 
FITC-dUTP, 3 nmol dATP (1 ul), 50 nmol CoCl2, 5 U terminal 
desoxynucleotidyltransferase and 10 ul reaction buffer 5X (sodium 
cacodylate 1 M, bovine serum albumin 1.25 mg/ml and Tris-HCl 
125 mM, pH 6.6). After incubation the nuclei were washed twice 
with PBS and were resuspended in 500 j_il PBS and analyzed cyto-
fluorimetrically as described [25]. 
2.4. Cytofluorimetric analyses of whole cells 
Cells were incubated during 15 min at 37°C with the potential -
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Fig. 1. Effect of different concentrations of NO donors on mito-
chondrial large amplitude swelling. Liver mitochondria were incu-
bated with variable doses of NO donors while assessing absorbtion 
at 540 nm as in Fig. 2A. The loss of absorption induced by ter-bu-
tylhydroperoxide (50 |j,M) within 5 min was considered as 100% of 
large amplitude swelling. 
sensitive dye 3,3'-dihexyloxacarbocyanine iodide (DiOQ(3); 40 nM; 
Molecular Probes), hydroethidine (HE; 2 U.M; Molecular Probes); the 
vital dye ethidium bromide (EthBr, 200 ng/ml) and/or an FITC-an-
nexin V conjugate (1:400 dilution; 1 ug/ml, 15 min at 4°C; Brand 
Applications, Maastricht, The Netherlands), as described [6,8,10,26], 
Labeling with FITC-annexin V was performed after removal of FCS 
by washing cells twice in HEPES buffer (10 mM HEPES-NaOH, pH 
7.4; 150 mM NaCl, 5 mM KC1, 1 mM MgCl2, 1.8 mM CaCl2) [27]. 
After incubation cells were immediately analyzed in an Epics Profile 
(Coulter) cytofluorometer (excitation 488 nm). Ethidium (Eth, the 
oxidation product of HE) and EthBr fluorescence was recorded in 
FL3; DiOC6(3) and FITC-annexin V in FL1. Hypoploidy was deter-
mined by staining of ethanol-fixed cells with propidium iodide, as 
described [26]. 
3. Results and discussion 
3.1. NO induces the mitochondrial release of apoptogenic 
factors concomitant with permeability transition 
Isolated mitochondria undergo rapid colloidosmotic swel-
ling indicative of PT [28,29] in response to three different N O 
donors (Fig. 1). This effect is observed with an E D 5 0 of ap-
proximately 25 n M (GSNO) to 100 n M (SIN-1, SNAP), cor-
responding to an effective ED 5 0 of N O of about 10 n M . N O -
induced swelling was efficiently inhibited by specific substan-
ces such as BA, CsA, and the non-immunosuppressive CsA 
derivative Af-methyl-4-valine-CsA (SDZ), which are known to 
inhibit PT [28,29] (Fig. 2A). We have previously shown that 
PT leads to the liberation of apoptogenic factors, that is fac-
tors which, in a cell free system, provoke signs of nuclear 
apoptosis (chromatin condensation and D N A fragmentation) 
[11,25]. As shown in Fig. 2B, N O treatment of isolated mito-
chondria also triggers the release of an activity that causes 
D N A fragmentation in isolated nuclei. The release of this 
activity into the supernatant is inhibited by the P T inhibitors 
BA, CsA, and Ar-methyl-4-valine-CsA (Fig. 2B), indicating 
that it is coupled to PT. In conclusion, N O induces both 
mitochondrial PT and PT-associated release of apoptogenic 
factors. 
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Fig. 2. NO causes permeability transition and liberation of apoptogenic factors from mitochondria. A: large amplitude swelling of mitochon-
dria. Liver mitochondria were incubated with NO donors (data shown for 100 nM GSNO) and/or the PT inhibitors bongkrekic acid (BA; 50 
uM), cyclosporin A (CsA; 10 uM), /Y-methyl-Val-4-cyclosporin A (SDZ 220-384, SDZ; 10 iiM). Arrows indicate the time points at which the 
NO donor was added to mitochondria. Similar results were obtained when instead of GSNO, another NO donor, SNAP (100 nM), was used 
(not shown). B: NO-treated mitochondria release apoptogenic factors. Liver mitochondria were incubated in the presence or absence of the 
same substances as in A, followed by ultracentrifugation (15000X105 Xg, 1 h) and recovery of supernatants. Isolated liver nuclei were incu-
bated in the presence of these supernatants (30 min, 37°C), followed by TUNEL staining to determine DNA strand breaks, as described in Sec-
tion 2. 
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Fig. 3. Kinetics of mitochondrial alterations, nuclear apoptosis and plasma membrane changes induced by NO. A: changes in the mitochon-
drial transmembrane potential ( A ^ ; measured with DiOQ(3)), superoxide anion generation (measured by means of the conversion of HE-
-»Eth), and nuclear apoptosis (hypoploid cells; black circles). Murine thymocytes were cultured in the presence or absence of the NO donor 
GSNO (1 mM). At the indicated time intervals, cells were stained with a combination of DiOCe(3) plus HE, during 15 min at 37°C. The per-
centage of hypoploid cells (numbers in black circles) was measured in ethanol-permeabilized cells stained with the DNA-intercalating dye propi-
dium iodide. B: exposure of phosphatidyl serine (PS) residues on the cell surface. Thymocytes cultured as in A were simultaneously stained 
with the vital dye EthBr and the phosphatidylserine-reactive FITC-annexin V. Comparable results were obtained when the NO donor SIN-1 
was used (not shown). 
3.2. Disruption of the mitochondrial inner transmembrane 
potential (A *Fm) is an early event in NO-induced apoptosis 
Thymocytes undergoing glucocorticoid-induced death ex-
hibit a reduction in mitochondrial transmembrane potential 
(A Wm) preceding exposure of phosphatidylserine residues on 
the plasma membrane, enhanced generation of superoxide 
anions, and nuclear DNA degradation [8,10]. Here, we show 
that NO-induced apoptosis follows a similar chronology. In-
cubation of mouse thymocytes with HE and DiOC6(3) allows 
for the simultaneous determination of A !f^  and mitochondrial 
ROS generation [8]. As demonstrated in Fig. 3A, thymocytes 
cultured in the presence of NO donors manifest a reduction in 
DiOCe(3) incorporation followed by an increased superoxide 
anion-driven HE->Eth conversion, as well as nuclear DNA 
loss. In addition to mitochondrial signs of apoptosis, we de-
termined plasma membrane alterations associated with the 
apoptotic process. Loss of membrane integrity was measured 
using ethidium bromide (EthBr), and the aberrant surface 
exposure of phosphatidylserine was monitored by means of 
an FITC-annexin V conjugate. As shown in Fig. 3B, NO also 
triggers the "flipping out" of phosphatidyl serine residues on 
yet viable (EthBr -) cells. As it has been observed for apop-
tosis triggered by the glucocorticoid receptor agonist DEX 
[10], the kinetic data suggest that Af^ disruption precedes 
phosphatidyl serine exposure and nuclear apoptosis (Fig. 3). 
3.3. Inhibition of PT prevents NO-induced apoptosis 
To determine whether PT is a rate-limiting event of NO-
induced apoptosis, we have taken advantage of three inhibi-
tors of PT, namely BA (a ligand of the adenine nucleotide 
translocator of the inner mitochondrial membrane), CsA and 
TY-methyl-L-Val-CsA (a ligand of mitochondrial matrix cyclo-
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Fig. 4. Effect of different PT inhibitors on apoptosis-associated changes in mitochondria, superoxide anion generation, nuclear DNA content 
and plasma membranes. Thymocytes were exposed to the indicated substances (GSNO 1 mM), BA (50 uM), CsA (10 uM), JV-methyl-Val-CsA 
(SDZ; 10 uM), or Z-VAD.fmk (50 uM) during 7 h. Thereafter, cells were labeled with HE, DiOC6(3) (A), FITC-annexin V, and EthBr (B). 
Numbers in circles (A) refer to the percentage of hypoploid cells determined by staining with propidium iodide. Results are representative for 
three independent experiments. 
philin) [12]. As shown in Fig. 4A, these agents inhibit the 
mitochondrial alterations induced by NO: A¥^n disruption 
and hyperproduction of superoxide anion. In addition, they 
effectively prevent nuclear DNA loss and phosphatidyl serine 
exposure on the outer leaflet of the plasma membrane (Fig. 
4B). The protease inhibitor Z-VAD.fmk, which neutralizes 
most of the apoptogenic activity contained in mitochondrial 
supernatants [25], can dissociate the mitochondrial and post-
mitochondrial signs of apoptosis induced by NO. Whereas Z-
VAD.fmk fails to stabilize the Atf^, it completely prevents 
nuclear apoptosis and strongly reduces phosphatidyl serine 
exposure (Fig. 4A,B). This suggests that Z-VAD.fmk-inhibit-
able proteases participate in the post-mitochondrial rather 
than in the mitochondrial phase of the NO-triggered apop-
totic process. 
3.4. Concluding remarks 
In this paper, we present data indicating that NO can trig-
ger apoptosis via inducing mitochondrial PT. This suggests 
that NO is triggering the same cascade of molecular events 
as do other apoptosis inducers including glucocorticoids, re-
active oxygen species, and p53-dependent genotoxic stress 
[6,8,10,12]: first mitochondrial PT with release of apoptogenic 
factors, then the nuclear and plasma membrane feature of 
advanced apoptosis. The idea that NO provokes apoptosis 
via induction of PT is in accord with the facts that Bcl-2 
hyperexpression prevents NO-induced apoptosis [4,5] and 
that Bcl-2 functions as an endogenous inhibitor of mitochon-
drial membrane changes associated with early apoptosis 
[8,10,11,25,30-33]. 
As a note of caution, however, it has to be stated that NO 
is not a universal inducer of apoptosis, perhaps due to differ-
ences in the expression level of members of the Bcl-2 family 
and/or differences in the capacity of NO detoxification in cell 
lines [34]. Moreover, it appears that, according to its pleio-
tropic nature, NO can trigger alternative apoptotic pathways. 
Thus, NO has been reported to upregulate the CD95/Fas/ 
Apo-1 death receptor on vascular smooth muscle cells [35], 
to trigger overexpression of the apoptosis-triggering protein 
p53 in a macrophage cell line [36], and to prevent N F K B 
binding to DNA, thus disrupting an apoptosis-inhibitory 
pathway [37]. Regardless of these additional possibilities, 
however, the present data suggest that, at least in certain 
cell types, NO may induce apoptosis via a direct effect on 
mitochondria. Future studies will have to elucidate which ex-
act molecular targets are modified by NO or peroxynitrate at 
the level of mitochondrial membranes. 
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